FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Operation TrialBlazer May Reshape Clinical Development: Ropes & Gray

[ Price : $8.95]

A Ropes & Gray legal update examines FDA initiatives to shorten drug development timelines and reduce regulatory burdens for spons...

Mixed Stakeholder Views on Priority Voucher Pilot

[ Price : $8.95]

Four stakeholders express varying opinions on the future direction and existence of the FDA national priority drug voucher program...

BlephEx 12-Page Warning Letter

[ Price : $8.95]

FDA warns Brentwood, TN-based BlephEx about multiple violations in its manufacturing of three unapproved ophthalmic devices.

FDA Pauses Release of Complete Response Letters as it Mulls Policy

[ Price : $8.95]

FDA temporarily suspends its controversial practice of publicly releasing Complete Response Letters for rejected drug applications...

J&J Wins Approval for Dual-Energy Cardiac Ablation Platform

[ Price : $8.95]

FDA approves Johnson & Johnsons Dual Energy Thermocool Smarttouch SF Platform, a catheter ablation system that combines pulsed fie...

LyfeUnit Selling Unapproved Ketamine Products: FDA

[ Price : $8.95]

FDA warns that the LyfeUnit Web site is selling unapproved adulterated and misbranded ketamine products.

FDA Moves to Cement Complete Response Letter Transparency Policy

[ Price : $8.95]

FDA looks to formalize one of its most significant transparency initiatives in decades: the public release of Complete Response Le...

Companies Can Use AI to Prepare for Inspections

[ Price : $8.95]

Former FDAer David Elder recommends that companies qualify AI tools to assist them in preparing for and responding to FDA inspecti...

QuVa Pharma Inspection Observations

[ Price : $8.95]

FDA releases the form FDA-483 with three observations from an inspection at the QuVa Pharma outsourcing facility in Sugar Land, TX...

Vera Therapeutics' Trutakna Approved for IgA Nephropathy

[ Price : $8.95]

FDA grants Vera Therapeutics an accelerated approval for Trutakna (atacicept-vymj) to reduce proteinuria in adults with primary im...